The high responder: a review of pathophysiology and outcomes during IVF treatment

References

• Abbara, A., Jayasena, C.N., Christopoulos, G., Narayanaswamy, S., Izzi-Engbeaya, C., Nijher, G.M.K., … Dhillo, W.S. (2015). Efficacy of Kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. Journal of Clinical Endocrinology and Metabolism, 100, 3322–3331. doi: 10.1210/jc.2015-2332.
   PubMed Web of Science ®Google Scholar
• Acet, M., Aktün, L.H., Başaranoğlu, S., Yorgunlar, B., Acet, T., & Deregözü, A. (2015). Premature progesterone elevation does not affect pregnancy outcome in high-responder patients undergoing short-interval coasting in IVF cycles. Medical Science Monitor Basic Research, 21, 247–252. doi: 10.12659/MSMBR.896244.
   PubMed Web of Science ®Google Scholar
• Akman, L., Sahin, G., Erbas, O., Aktug, H., Akdogan, A., Goker, E.N.T., … Tavmergen, E. (2015). Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: In an experimental rat model. Gynecological Endocrinology, 31, 369–373. doi: 10.3109/09513590.2014.1000849.
   PubMed Web of Science ®Google Scholar
• Al-Inany, H., & Aboulghar, M. (2001). Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database of Systematic Reviews, 2001, CD001750. doi: 10.1002/14651858.CD001750.
   Google Scholar
• Al-Inany, H.G., Abou-Setta, A.M., & Aboulghar, M. (2006). Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database of Systematic Reviews, 2006, CD001750. doi: 10.1002/14651858.CD001750.pub2.
   Web of Science ®Google Scholar
• Al-Inany, H.G., Youssef, M.A., Aboulghar, M., Broekmans, F., Sterrenburg, M., Smit, J., & Abou-Setta, A.M. (2011). Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews, 2011, CD001750. doi: 10.1002/14651858.CD001750.pub3.
   Web of Science ®Google Scholar
• Allersma, T., Farquhar, C., & Cantineau, A.E.P. (2013). Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database of Systematic Reviews, 2013, CD010550. doi: 10.1002/14651858.CD010550.pub2.
   Web of Science ®Google Scholar
• Andersen, C.Y., & Andersen, K.V. (2014). Improving the luteal phase after ovarian stimulation: reviewing new options. Reproductive Biomedicine Online, 28, 552–559. doi: 10.1016/j.rbmo.2014.01.012.
   PubMed Web of Science ®Google Scholar
• Andersen, C.Y., Westergaard, L.G., & van Wely, M. (2004). FSH isoform composition of commercial gonadotrophin preparations: A neglected aspect? Reproductive Biomedicine Online, 9, 231–236. doi: 10.1016/S1472-6483(10)62135-9.
   PubMed Web of Science ®Google Scholar
• Asch, R.H., Li, H.P., Balmaceda, J.P., Weckstein, L.N., & Stone, S.C. (1991). Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Human Reproduction, 6, 1395–1399. Retrieved from http://humrep.oxfordjournals.org/content/6/10/1395.abstract
   PubMed Web of Science ®Google Scholar
• Baart, E.B., Martini, E., Eijkemans, M.J., Van Opstal, D., Beckers, N.G.M., Verhoeff, A., … Fauser, B.C.J.M. (2007). Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: A randomized controlled trial. Human Reproduction, 22, 980–988. doi: 10.1093/humrep/del484.
   PubMed Web of Science ®Google Scholar
• Beall, S.A., & Decherney, A. (2012). The history and challenges surrounding ovarian stimulation in the treatment of infertility. Fertility and Sterility, 97, 795–801. doi: 10.1016/j.fertnstert.2012.02.030.
   PubMed Web of Science ®Google Scholar
• Bosch, E., Labarta, E., Kolibianakis, E., Rosen, M., & Meldrum, D. (2016). Regimen of ovarian stimulation affects oocyte and therefore embryo quality. Fertility and Sterility, 105, 560–570. doi: 10.1016/j.fertnstert.2016.01.022.
   PubMed Web of Science ®Google Scholar
• Bourgain, C., & Devroey, P. (2003). The endometrium in stimulated cycles for IVF. Human Reproduction Update, 9, 515–522. doi: 10.1093/humupd/dmg045.
   PubMed Web of Science ®Google Scholar
• Broer, S.L., Dólleman, M., Opmeer, B.C., Fauser, B.C., Mol, B.W., & Broekmans, F.J.M. (2011). AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Human Reproduction Update, 17, 46–54. doi: 10.1093/humupd/dmq034.
   PubMed Web of Science ®Google Scholar
• Cakmak, H., & Taylor, H.S. (2011). Implantation failure: Molecular mechanisms and clinical treatment. Human Reproduction Update, 17, 242–253. doi: 10.1093/humupd/dmq037.
   PubMed Web of Science ®Google Scholar
• Cano, F., García-Velasco, J.A., Millet, A., Remohí, J., Simón, C., & Pellicer, A. (1997). Oocyte quality in polycystic ovaries revisited: Identification of a particular subgroup of women. Journal of Assisted Reproduction and Genetics, 14, 254–261. doi: 10.1007/BF02765826.
   PubMed Web of Science ®Google Scholar
• Capalbo, A., Bono, S., Spizzichino, L., Biricik, A., Baldi, M., Colamaria, S., … Fiorentino, F. (2013). Sequential comprehensive chromosome analysis on polar bodies, blastomeres and trophoblast: Insights into female meiotic errors and chromosomal segregation in the preimplantation window of embryo development. Human Reproduction, 28, 509–518. doi: 10.1093/humrep/des394.
   PubMed Web of Science ®Google Scholar
• Cenksoy, C., Cenksoy, P.O., Erdem, O., Sancak, B., & Gursoy, R. (2014). A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. European Journal of Obstetrics, Gynecology and Reproductive Biology, 174, 86–90. doi: 10.1016/j.ejogrb.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Cermik, D., Selam, B., & Taylor, H.S. (2003). Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 88, 238–243. doi: 10.1210/jc.2002-021072.
   PubMed Web of Science ®Google Scholar
• Choux, C., Carmignac, V., Bruno, C., Sagot, P., Vaiman, D., & Fauque, P. (2015). The placenta: phenotypic and epigenetic modifications induced by assisted reproductive technologies throughout pregnancy. Clinical Epigenetics, 7, 87. doi: 10.1186/s13148-015-0120-2.
   PubMed Web of Science ®Google Scholar
• Colacurci, N., Caprio, F., La Verde, E., Trotta, C., Ianniello, R., Mele, D., & De Franciscis, P. (2014). Sequential protocol with urinary-FSH/recombinant-FSH versus standard protocol with recombinant-FSH in women of advanced age undergoing IVF. Gynecological Endocrinology, 30, 730–733. doi: 10.3109/09513590.2014.927856.
   PubMed Web of Science ®Google Scholar
• Cree, L.M., Hammond, E.R., Shelling, A.N., Berg, M.C., Peek, J.C., & Green, M.P. (2015). Maternal age and ovarian stimulation independently affect oocyte mtDNA copy number and cumulus cell gene expression in bovine clones. Human Reproduction, 30, 1410–1420. doi: 10.1093/humrep/dev066.
   PubMed Web of Science ®Google Scholar
• Dahdouh, E.M., Balayla, J., & García-Velasco, J.A. (2015). Impact of blastocyst biopsy and comprehensive chromosome screening technology on preimplantation genetic screening: A systematic review of randomized controlled trials. Reproductive Biomedicine Online, 30, 281–289. doi: 10.1016/j.rbmo.2014.11.015.
   PubMed Web of Science ®Google Scholar
• D’Angelo, A., & Amso, N. (2007). Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2007, CD002806. doi: 10.1002/14651858.CD002806.pub2.
   Web of Science ®Google Scholar
• D’Angelo, A., Brown, J., & Amso, N.N. (2011). Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2011, CD002811. doi: 10.1002/14651858.CD002811.pub3.
   Web of Science ®Google Scholar
• Das, M., Son, W.Y., Buckett, W., Tulandi, T., & Holzer, H. (2014). In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: Treatment outcome and rates of ovarian hyperstimulation syndrome. Reproductive Biomedicine Online, 29, 545–551. doi: 10.1016/j.rbmo.2014.07.019.
   PubMed Web of Science ®Google Scholar
• Devroey, P., Polyzos, N.P., & Blockeel, C. (2011). An OHSS-Free Clinic by segmentation of IVF treatment. Human Reproduction, 26, 2593–2597. doi: 10.1093/humrep/der251.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis, E., & Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocrine Reviews, 33, 981–1030. doi: 10.1210/er.2011-1034.
   PubMed Web of Science ®Google Scholar
• Diedrich, K., Diedrich, C., Santos, E., Zoll, C., Al-Hasani, S., Reissmann, T., … Klingmüller, D. (1994). Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Human Reproduction, 9, 788–791. Retrieved from http://humrep.oxfordjournals.org/content/9/5/788
   PubMed Web of Science ®Google Scholar
• Di Lorenzo, G., Ceccarello, M., Cecotti, V., Ronfani, L., Monasta, L., Vecchi Brumatti, L., … D'ottavio, G. (2012). First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta, 33, 495–501. doi: 10.1016/j.placenta.2012.03.003.
   PubMed Web of Science ®Google Scholar
• Engmann, L., DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D., & Benadiva, C. (2008). The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertility and Sterility, 89, 84–91. doi: 10.1016/j.fertnstert.2007.02.002.
   PubMed Web of Science ®Google Scholar
• Eppig, J.J., O’brien, M.J., Pendola, F.L., & Watanabe, S. (1998). Factors affecting the developmental competence of mouse oocytes grown in vitro: Follicle-stimulating hormone and insulin. Biology of Reproduction, 59, 1445–1453. doi: 10.1095/biolreprod59.6.1445.
   PubMed Web of Science ®Google Scholar
• ESHRE. (2016). ART fact sheet. (2016, March 19). Retrieved from https://www.eshre.eu/∼/media/sitecore-files/Guidelines/ART-fact-sheet-2016.pdf?la=en
   Google Scholar
• Evans, J., & Salamonsen, L.A. (2013). Too much of a good thing? Experimental evidence suggests prolonged exposure to hCG is detrimental to endometrial receptivity. Human Reproduction, 28, 1610–1619. doi: 10.1093/humrep/det055.
   PubMed Web of Science ®Google Scholar
• Ferraretti, A.P., Marca, A.L., Fauser, B.C.J.M., Tarlatzis, B., Nargund, G., & Gianaroli, L. on behalf of the ESHRE working group on Poor Ovarian Response Definition. (2011). ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction, 26, 1616–1624. doi: 10.1093/humrep/der092.
   PubMed Web of Science ®Google Scholar
• Frolova, A.I., & Moley, K.H. (2011). Glucose transporters in the uterus: An analysis of tissue distribution and proposed physiological roles. Reproduction, 142, 211–220.doi: 10.1530/REP-11-0114.
   PubMed Web of Science ®Google Scholar
• GeneCards. (2015). SLC2A4 Gene (Protein Coding) Solute Carrier Family 2 Member 4. GeneCards Human Gene Database, Weizmann Institute of Science. [cited 2015 Sep 13]. Retrieved from http://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC2A4
   Google Scholar
• Giorgetti, C., Vanden Meerschaut, F., De Roo, C., Saunier, O., Quarello, E., Hairion, D., … De Sutter, P. (2013). Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies. Human Reproduction, 28, 2636–2642. doi: 10.1093/humrep/det295.
   PubMed Web of Science ®Google Scholar
• Gomez, R., Gonzalez-Izquierdo, M., Zimmermann, R.C., Novella-Maestre, E., Alonso-Muriel, I., Sanchez-Criado, J., … Pellicer, A. (2006). Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology, 147, 5400–5411. doi: 10.1210/en.2006-0657.
   PubMed Web of Science ®Google Scholar
• Gonzalez, D., Thackeray, H., Lewis, P.D., Mantani, A., Brook, N., Ahuja, K., … Conlan, R.S. (2012). Loss of WT1 expression in the endometrium of infertile PCOS patients: A hyperandrogenic effect?. Journal of Clinical Endocrinology and Metabolism, 97, 957–966. doi: 10.1210/jc.2011-2366.
   PubMed Web of Science ®Google Scholar
• Griffinn˙, D., Benadiva, C., Kummer, N., Budinetz, T., Nulsen, J., & Engmann, L. (2012). Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility and Sterility, 97, 1316–1320.doi: 10.1016/j.fertnstert.2012.03.015.
   PubMed Web of Science ®Google Scholar
• Guerre-Millo, M. (2008). Adiponectin: an update. Diabetes Metab, 34, 12–18.doi: 10.1016/j.diabet.2007.08.002.
   PubMed Web of Science ®Google Scholar
• Gurgan, T., Montjean, D., Demirol, A., & Menezo, Y.J.R. (2014). Sequential (hFSH + recFSH) vs homogenous (hFSH or recFSH alone) stimulation: Clinical and biochemical (cumulus cell gene expression) aspects. Journal of Assisted Reproduction and Genetics, 31, 657–665. doi: 10.1007/s10815-014-0208-1.
   PubMed Web of Science ®Google Scholar
• Gurbuz, A.S., Gode, F., Ozcimen, N., & Isik, A.Z. (2014). Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reproductive Biomedicine Online, 29, 541–544. doi: 10.1016/j.rbmo.2014.07.022.
   PubMed Web of Science ®Google Scholar
• Haas, J., Kedem, A., Machtinger, R., Dar, S., Hourvitz, A., Yerushalmi, G., & Orvieto, R. (2014). HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept. Journal of Ovarian Research, 7, 35. doi: 10.1186/1757-2215-7-35.
   PubMed Web of Science ®Google Scholar
• Haouzi, D., Assou, S., Monzo, C., Vincens, C., Dechaud, H., & Hamamah, S. (2012). Altered gene expression profile in cumulus cells of mature MII oocytes from patients with polycystic ovary syndrome. Human Reproduction, 27, 3523–3530.doi: 10.1093/humrep/des325.
   PubMed Web of Science ®Google Scholar
• Harris, S.E., Maruthini, D., Tang, T., Balen, A.H., & Picton, H.M. (2010). Metabolism and karyotype analysis of oocytes from patients with polycystic ovary syndrome. Human Reproduction, 25, 2305–2315.doi: 10.1093/humrep/deq181.
   PubMed Web of Science ®Google Scholar
• Heijnen, E.M.E.W., Eijkemans, M.J.C., Hughes, E.G., Laven, J.S.E., Macklon, N.S., & Fauser, B.C.J.M. (2006). A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Human Reproduction Update, 12, 13–21.doi: 10.1093/humupd/dmi036.
   PubMed Web of Science ®Google Scholar
• Horcajadas, J.A., Riesewijk, A., Polman, J., van Os, R., Pellicer, A., Mosselman, S., & Simón, C. (2005). Effect of controlled ovarian hyperstimulation in IVF on endometrial gene expression profiles. Molecular Human Reproduction, 11, 195–205. doi: 10.1093/molehr/gah150.
   PubMed Web of Science ®Google Scholar
• Humaidan, P. (2009). Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reproductive Biomedicine Online, 18, 630–634.doi: 10.1016/S1472-6483(10)60006-5.
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Polyzos, N.P., Alsbjerg, B., Erb, K., Mikkelsen, A.L., Elbaek, H.O., … Andersen, C.Y. (2013). GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Human Reproduction, 28, 2511–2521. doi: 10.1093/humrep/det249.
   PubMed Web of Science ®Google Scholar
• Iliodromiti, S., Blockeel, C., Tremellen, K.P., Fleming, R., Tournaye, H., Humaidan, P., & Nelson, S.M. (2013). Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Human Reproduction, 28, 2529–2536.doi: 10.1093/humrep/det304.
   PubMed Web of Science ®Google Scholar
• Itskovitz-Eldor, J., Kol, S., & Mannaerts, B. (2000). Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Human Reproduction, 15, 1965–1968.doi: 10.1093/humrep/15.9.1965.
   PubMed Web of Science ®Google Scholar
• Kashyap, S., Parker, K., Cedars, M.I., & Rosenwaks, Z. (2010). Ovarian hyperstimulation syndrome prevention strategies: reducing the human chorionic gonadotropin trigger dose. Seminars in Reproductive Medicine, 28, 475–485.doi: 10.1055/s-0030-1265674.
   PubMed Web of Science ®Google Scholar
• Kwan, I., Bhattacharya, S., Kang, A., & Woolner, A. (2014). Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database of Systematic Reviews, 2014, CD005289. doi: 10.1002/14651858.CD005289.pub3.
   Web of Science ®Google Scholar
• Lainas, G.T., Kolibianakis, E.M., Sfontouris, I.A., Zorzovilis, I.Z., Petsas, G.K., Lainas, T.G., & Tarlatzis, B.C. (2013). Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Human Reproduction, 28, 1929–1942.doi: 10.1093/humrep/det114.
   PubMed Web of Science ®Google Scholar
• Lainas, T.G., Sfontouris, I.A., Zorzovilis, I.Z., Petsas, G.K., Lainas, G.T., & Kolibianakis, E.M. (2007). Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reproductive Biomedicine Online, 15, 408–412.doi: 10.1016/S1472-6483(10)60366-5.
   PubMed Web of Science ®Google Scholar
• La Marca, A., Grisendi, V., Giulini, S., Argento, C., Tirelli, A., Dondi, G., … Volpe, A. (2013). Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. Journal of Ovarian Research, 6, 11. doi: 10.1186/1757-2215-6-11.
   PubMed Web of Science ®Google Scholar
• La Marca, A., Papaleo, E., Grisendi, V., Argento, C., Giulini, S., & Volpe, A. (2012). Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG, 119, 1171–1179.doi: 10.1111/j.1471-0528.2012.03412.x.
   PubMed Web of Science ®Google Scholar
• Leary, C., Leese, H.J., & Sturmey, R.G. (2015). Human embryos from overweight and obese women display phenotypic and metabolic abnormalities. Human Reproduction, 30, 122–132.doi: 10.1093/humrep/deu276.
   PubMed Web of Science ®Google Scholar
• Lee, T.H., Liu, C.H., Huang, C.C., Wu, Y.L., Shih, Y.T., Ho, H.N., … Lee, M.S. (2008). Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Human Reproduction, 23, 160–167. doi: 10.1093/humrep/dem254.
   PubMed Web of Science ®Google Scholar
• Lessey, B.A. (2000). Endometrial receptivity and the window of implantation. Baillieère's Best Practice & Research. Clinical Obstetrics & Gynaecology, 14, 775–788.doi: 10.1053/beog.2000.0118.
   PubMed Web of Science ®Google Scholar
• Leth-Moller, K., Hammer Jagd, S., & Humaidan, P. (2014). The luteal phase after GnRHa trigger-understanding an enigma. International Journal of Fertility and Sterility, 8, 227–234. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221507/
   PubMedGoogle Scholar
• Lin, Y.H., Hwang, J.L., Huang, L.W., Mu, S.C., Seow, K.M., Chung, J., … Chen, P.H. (2003). Combination of FSH priming and hCG priming for in‐vitro maturation of human oocytes. Human Reproduction, 18, 1632–1636. doi: 10.1093/humrep/deg335.
   PubMed Web of Science ®Google Scholar
• Liu, S., Zhang, X., Shi, C., Lin, J., Chen, G., Wu, B., … Wang, J. (2015). Altered microRNAs expression profiling in cumulus cells from patients with polycystic ovary syndrome. Journal of Translational Medicine, 13, 238. doi: 10.1186/s12967-015-0605-y.
   PubMed Web of Science ®Google Scholar
• Martínez, F., Rodríguez, D.B., Buxaderas, R., Tur, R., Mancini, F., & Coroleu, B. (2011). GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports. Fertility and Sterility, 95, 2432.e17–2432.e19. doi: 10.1016/j.fertnstert.2011.03.083.
   PubMed Web of Science ®Google Scholar
• Mascarenhas, M., Kamath, M.S., Chandy, A., & Kunjummen, A.T. (2015). Progesterone/estradiol ratio as a predictor in the ART cycles with premature progesterone elevation on the day of hCG trigger. Journal of Reproduction and Infertility, 16, 155–161. Retrieved from http://en.journals.sid.ir/ViewPaper.aspx?ID=450551
   PubMedGoogle Scholar
• Mioni, R., Chiarelli, S., Xamin, N., Zuliani, L., Granzotto, M., Mozzanega, B., … Vettor, R. (2004). Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. Journal of Clinical Endocrinology and Metabolism, 89, 4089–4096. doi: 10.1210/jc.2003-032028.
   PubMed Web of Science ®Google Scholar
• Morris, R.S., Paulson, R.J., Sauer, M.V., & Lobo, R.A. (1995). Endocrinology: Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Human Reproduction, 10, 811–814. Retrieved from http://humrep.oxfordjournals.org/content/10/4/811.abstract
   PubMed Web of Science ®Google Scholar
• Mozzanega, B., Mioni, R., Granzotto, M., Chiarelli, S., Xamin, N., Zuliani, L., … Vettor, R. (2004). Obesity reduces the expression of GLUT4 in the endometrium of normoinsulinemic women affected by the polycystic ovary syndrome. Annals of the New York Academy of Sciences, 1034, 364–374. doi: 10.1196/annals.1335.038.
   PubMed Web of Science ®Google Scholar
• NICE. (2016). Fertility problems: assessment and treatment. Clinical guideline [CG156]. National Institute for Health and Care Excellence. (2016, March 19). Retrieved from https://www.nice.org.uk/guidance/cg156/chapter/1-recommendations
   Google Scholar
• Nicholas, S., Brewer, C., Tang, T., & Balen, A. (2015). Metformin and the antagonist cycle – a step too far. Human Fertility, 18, 293. doi: 10.3109/14647273.2015.1060045.
   Google Scholar
• Olivennes, F., Howles, C.M., Borini, A., Germond, M., Trew, G., Wikland, M., … Alam, V. (2009). Individualizing FSH dose for assisted reproduction using a novel algorithm: The CONSORT study. Reproductive Biomedicine Online, 18, 195–204. doi: 10.1016/S1472-6483(10)60256-8.
   PubMed Web of Science ®Google Scholar
• Orvieto, R. (2003). Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Human Reproduction, 18, 665–667.doi: 10.1093/humrep/deg166.
   PubMed Web of Science ®Google Scholar
• Palep-Singh, M., Picton, H.M., Vrotsou, K., Maruthini, D., & Balen, A.H. (2007). South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. European Journal of Obstetrics, Gynecology and Reproductive Biology, 134, 202–207.doi: 10.1016/j.ejogrb.2007.02.005.
   PubMed Web of Science ®Google Scholar
• Palomba, S., Falbo, A., & La Sala, G.B. (2013). Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG, 120, 267–276.doi: 10.1111/1471-0528.12070.
   PubMed Web of Science ®Google Scholar
• Papageorgiou, T., Guibert, J., Goffinet, F., Patrat, C., Fulla, Y., Janssens, Y., & Zorn, J.R. (2002). Percentile curves of serum estradiol levels during controlled ovarian stimulation in 905 cycles stimulated with recombinant FSH show that high estradiol is not detrimental to IVF outcome. Human Reproduction, 17, 2846–2850.doi: 10.1093/humrep/17.11.2846.
   PubMed Web of Science ®Google Scholar
• Papanikolaou, E.G., Humaidan, P., Polyzos, N.P., & Tarlatzis, B. (2010). Identification of the high-risk patient for ovarian hyperstimulation syndrome. Seminars in Reproductive Medicine, 28, 458–462.doi: 10.1055/s-0030-1265671.
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists (2016). The Management of Ovarian Hyperstimulation Syndrome. RCOG Green-top Guideline No. 5. Retrieved from https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_5_ohss.pdf
   Google Scholar
• Rizk, B. (2009). Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome. Reproductive Biomedicine Online, 19, 14–27.doi: 10.1016/S1472-6483(10)60041-7.
   PubMed Web of Science ®Google Scholar
• Rubio, C., Mercader, A., Alamá, P., Lizán, C., Rodrigo, L., Labarta, E., … Remohí, J. (2010). Prospective cohort study in high responder oocyte donors using two hormonal stimulation protocols: impact on embryo aneuploidy and development. Human Reproduction, 25, 2290–2297. doi: 10.1093/humrep/deq174.
   PubMed Web of Science ®Google Scholar
• Selman, H., Pacchiarotti, A., & El-Danasouri, I. (2010). Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: Impact on oocyte quality and clinical outcome. Fertility and Sterility, 94, 1782–1786.doi: 10.1016/j.fertnstert.2009.10.005.
   PubMed Web of Science ®Google Scholar
• Selman, H., Pacchiarotti, A., Rinaldi, L., Crescenzi, F., Lanzilotti, G., Lofino, S., & El-Danasouri, I. (2013). Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures. European Review for Medical and Pharmacological Sciences, 17, 1814–1819. Retrieved from https://sapienza.pure.elsevier.com/en/publications/simultaneous-administration-of-human-acidic-and-recombinant-less-
   PubMed Web of Science ®Google Scholar
• Sengoku, K., Tamate, K., Takuma, N., Yoshida, T., Goishi, K., & Ishikawa, M. (1997). The chromosomal normality of unfertilized oocytes from patients with polycystic ovarian syndrome. Human Reproduction, 12, 474–477.doi: 10.1093/humrep/12.3.474.
   PubMed Web of Science ®Google Scholar
• Seyhan, A., Ata, B., Polat, M., Son, W.Y., Yarali, H., & Dahan, M.H. (2013). Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Human Reproduction, 28, 2522–2528. doi: 10.1093/humrep/det124.
   PubMed Web of Science ®Google Scholar
• Shavit, T., Ellenbogen, A., Michaeli, M., Kartchovsky, E., Ruzov, O., & Shalom-Paz, E. (2014). In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: Can superiority be defined? European Journal of Obstetrics, Gynecology and Reproductive Biology, 179, 46–50.doi: 10.1016/j.ejogrb.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Siristatidis, C.S., Vrachnis, N., Creatsa, M., Maheshwari, A., & Bhattacharya, S. (2013). In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database of Systematic Reviews, 2013, CD006606. doi: 10.1002/14651858.CD006606.pub3.
   Web of Science ®Google Scholar
• Smulders, B., van Oirschot, S.M., Farquhar, C., Rombauts, L., & Kremer, J.A. (2010). Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database of Systematic Reviews, 2010, CD006109. doi: 10.1002/14651858.CD006109.pub2.
   Web of Science ®Google Scholar
• Steiner, C.A., Janez, A., Jensterle, M., Reisinger, K., Forst, T., & Pfützner, A. (2007). Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. Journal of Diabetes Science and Technology, 1, 211–217. doi: 10.1177/193229680700100212.
   PubMedGoogle Scholar
• Steward, R.G., Lan, L., Shah, A.A., Yeh, J.S., Price, T.M., Goldfarb, J.M., & Muasher, S.J. (2014). Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertility and Sterility, 101, 967–973.doi: 10.1016/j.fertnstert.2013.12.026.
   PubMed Web of Science ®Google Scholar
• Steward, R.G., Zhang, C.E., Shah, A.A., Yeh, J.S., Chen, C., Li, Y.J., … Muasher, S.J. (2015). High peak estradiol predicts higher miscarriage and lower live birth rates in high responders triggered with a GnRH agonist in IVF/ICSI cycles. Journal of Reproductive Medicine, 60, 463–470. Retrieved from https://scholars.duke.edu/display/pub1111000
   PubMed Web of Science ®Google Scholar
• Sundvall, L., Kirkegaard, K., Ingerslev, H.J., & Knudsen, U.B. (2015). Unaltered timing of embryo development in women with polycystic ovarian syndrome (PCOS): A time-lapse study. Journal of Assisted Reproduction and Genetics, 32, 1031–1042.doi: 10.1007/s10815-015-0488-0.
   PubMed Web of Science ®Google Scholar
• Takemura, Y., Osuga, Y., Yamauchi, T., Kobayashi, M., Harada, M., Hirata, T., … Taketani, Y. (2006). Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology, 147, 3203–3210. doi: 10.1210/en.2005-1510.
   PubMed Web of Science ®Google Scholar
• Tan, B.K., & Mathur, R. (2013). Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee. Human Fertility, 16, 151–159.doi: 10.3109/14647273.2013.788313.
   Web of Science ®Google Scholar
• Tan, B.K., & Mathur, R. British Fertility Society Policy and Practice Subcommittee. (2013). Management of ovarian hyperstimulation syndrome guidelines. Produced on behalf of the BFS Policy and Practice Committee. Human Fertility, 16, 160–161.doi: 10.3109/14647273.2013.788325.
   Web of Science ®Google Scholar
• Tang, H., Hunter, T., Hu, Y., Zhai, S.D., Sheng, X., & Hart, R.J. (2012). Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2012, CD008605. doi: 10.1002/14651858.CD008605.pub2.
   Web of Science ®Google Scholar
• Tarkun, I., Dikmen, E., Cetinarslan, B., & Cantürk, Z. (2010). Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. European Cytokine Network, 21, 272–277. doi: 10.1684/ecn.2010.0217.
   PubMed Web of Science ®Google Scholar
• The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2008). Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction, 23, 462–477.doi: 10.1093/humrep/dem426.
   PubMed Web of Science ®Google Scholar
• Toulis, K.A., Goulis, D.G., Farmakiotis, D., Georgopoulos, N.A., Katsikis, I., Tarlatzis, B.C., … Panidis, D. (2009). Adiponectin levels in women with polycystic ovary syndrome: A systematic review and a meta-analysis. Human Reproduction Update, 15, 297–307. doi: 10.1093/humupd/dmp006.
   PubMed Web of Science ®Google Scholar
• Tso, L.O., Costello, M.F., Albuquerque, L.E.T., Andriolo, R.B., & Macedo, C.R. (2014). Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2014, CD006105. doi: 10.1002/14651858.CD006105.pub3.
   Web of Science ®Google Scholar
• Tuckerman, E.M., Okon, M.A., Li, T., & Laird, S.M. (2000). Do androgens have a direct effect on endometrial function? An in vitro study. Fertility and Sterility, 74, 771–779.doi: 10.1016/S0015-0282(00)00711-1.
   PubMed Web of Science ®Google Scholar
• van Wely, M., Kwan, I., Burt, A.L., Thomas, J., Vail, A., Van der Veen, F., & Al-Inany, H.G. (2011). Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, 2011, CD005354. doi: 10.1002/14651858.CD005354.pub2.
   Web of Science ®Google Scholar
• Venetis, C.A., Kolibianakis, E.M., Toulis, K.A., Goulis, D.G., Papadimas, I., & Tarlatzis, B.C. (2011). Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertility and Sterility, 95, 188–196.e3.doi: 10.1016/j.fertnstert.2010.05.026.
   PubMed Web of Science ®Google Scholar
• von Wolff, M., Ursel, S., Hahn, U., Steldinger, R., & Strowitzki, T. (2003). Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy. Journal of Clinical Endocrinology and Metabolism, 88, 3885–3892.doi: 10.1210/jc.2002-021890.
   PubMed Web of Science ®Google Scholar
• Walls, M.L., Hunter, T., Ryan, J.P., Keelan, J.A., Nathan, E., & Hart, R.J. (2015). In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: A comparative analysis of fresh, frozen and cumulative cycle outcomes. Human Reproduction, 30, 88–96.doi: 10.1093/humrep/deu248.
   PubMed Web of Science ®Google Scholar
• Walls, M.L., Ryan, J.P., Keelan, J.A., & Hart, R. (2015). In vitro maturation is associated with increased early embryo arrest without impairing morphokinetic development of useable embryos progressing to blastocysts. Human Reproduction, 30, 1842–1849.doi: 10.1093/humrep/dev125.
   PubMed Web of Science ®Google Scholar
• Wang, Y.Q., Luo, J., Xu, W.M., Xie, Q.Z., Yan, W.J., Wu, G.X., & Yang, J. (2015). Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?. Journal of Ovarian Research, 8, 63. doi: 10.1186/s13048-015-0190-y.
   PubMed Web of Science ®Google Scholar
• Wang, Y.Q., Yu, N., Xu, W.M., Xie, Q.Z., Yan, W.J., Wu, G.X., & Yang, J. (2014). Cetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study. Experimental and Therapeutic Medicine, 8, 1855–1860. doi: 10.3892/etm.2014.2005.
   PubMed Web of Science ®Google Scholar
• Weghofer, A., Munne, S., Chen, S., Barad, D., & Gleicher, N. (2007). Lack of association between polycystic ovary syndrome and embryonic aneuploidy. Fertility and Sterility, 88, 900–905.doi: 10.1016/j.fertnstert.2006.12.018.
   PubMed Web of Science ®Google Scholar
• Wide, L., & Bakos, O. (1993). More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at midcycle compared with the follicular or luteal phase. J. Clin. Endocrinol. Metab, 76, 885–889.doi: 10.1210/jcem.76.4.8473400.
   PubMed Web of Science ®Google Scholar
• Wijeyaratne, C.N., Balen, A.H., Barth, J.H., & Belchetz, P.E. (2002). Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clinical Endocrinology, 57, 343–350.doi: 10.1046/j.1365-2265.2002.01603.x.
   PubMed Web of Science ®Google Scholar
• Wissing, M.L., Bjerge, M.R., Olesen, A.I.G., Hoest, T., & Mikkelsen, A.L. (2014). Impact of PCOS on early embryo cleavage kinetics. Reproductive Biomedicine Online, 28, 508–514.doi: 10.1016/j.rbmo.2013.11.017.
   PubMed Web of Science ®Google Scholar
• Wood, J.R., Dumesic, D.A., Abbott, D.H., & Strauss, J.F. (2007). Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. Journal of Clinical Endocrinology and Metabolism, 92, 705–713.doi: 10.1210/jc.2006-2123.
   PubMed Web of Science ®Google Scholar
• Youssef, M.A., Al-Inany, H.G., Evers, J.L., & Aboulghar, M. (2011). Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews, 2011, CD001302. doi: 10.1002/14651858.CD001302.pub2.
   Web of Science ®Google Scholar
• Youssef, M.A.F.M., Van der Veen, F., Al-Inany, H.G., Mochtar, M.H., Griesinger, G., Nagi Mohesen, M., … vanWely, M. (2014). Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews, 2014, CD008046. doi: 10.1002/14651858.CD008046.pub4.
   Web of Science ®Google Scholar
• Zhai, J., Liu, C., Tian, Z., Jiang, Q., & Sun, Y. (2012). Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. Biology of Reproduction, 87, 29. doi: 10.1095/biolreprod.112.099788.
   PubMed Web of Science ®Google Scholar
• Zhu, R., Xiao, S., Zhao, J., Lin, J., Wang, P., Jin, C., & Jin, W.M. (2013). Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi, 48, 833–837. doi: 10.3760/cma.j.issn.0529-567x.2013.11.008.
   PubMedGoogle Scholar